<SEC-DOCUMENT>0001104659-25-112690.txt : 20251114
<SEC-HEADER>0001104659-25-112690.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114165426
ACCESSION NUMBER:		0001104659-25-112690
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avalo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001534120
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450705648
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89290
		FILM NUMBER:		251487789

	BUSINESS ADDRESS:	
		STREET 1:		1500 LIBERTY RIDGE DRIVE
		STREET 2:		SUITE 321
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		410-522-8707

	MAIL ADDRESS:	
		STREET 1:		1500 LIBERTY RIDGE DRIVE
		STREET 2:		SUITE 321
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerecor Inc.
		DATE OF NAME CHANGE:	20111102

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nantahala Capital Management, LLC
		CENTRAL INDEX KEY:			0001472322
		ORGANIZATION NAME:           	
		EIN:				201151760
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		130 MAIN ST.
		STREET 2:		2ND FLOOR
		CITY:			NEW CANAAN
		STATE:			CT
		ZIP:			06840
		BUSINESS PHONE:		203-404-1172

	MAIL ADDRESS:	
		STREET 1:		130 MAIN ST.
		STREET 2:		2ND FLOOR
		CITY:			NEW CANAAN
		STATE:			CT
		ZIP:			06840
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-25-049515</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Nantahala Capital Management, LLC -->
          <cik>0001472322</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001534120</issuerCik>
        <issuerName>AVALO THERAPEUTICS, INC.</issuerName>
        <issuerCusip>05338F306</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>1500 LIBERTY RIDGE DRIVE</com:street1>
          <com:street2>SUITE 321</com:street2>
          <com:city>WAYNE</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19087</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Nantahala Capital Management, LLC</reportingPersonName>
      <citizenshipOrOrganization>MA</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1235000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1235000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1235000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.39</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Wilmot B. Harkey</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1235000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1235000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1235000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.39</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Daniel Mack</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1235000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1235000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1235000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.39</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>AVALO THERAPEUTICS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE, PENNSYLVANIA, 19087</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>(1) Nantahala Capital Management, LLC ("Nantahala")
(2) Wilmot B. Harkey
(3) Daniel Mack (together the "Reporting Persons")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>130 Main St.  2nd Floor, New Canaan, Connecticut 06840</principalBusinessOfficeOrResidenceAddress>
        <citizenship>(1) Nantahala is a Massachusetts limited liability company.
(2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>IA</typeOfPersonFiling>
        <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of September 30, 2025, Nantahala may be deemed to be the beneficial owner of 1,235,000 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.</amountBeneficiallyOwned>
        <classPercent>As of September 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding:
(1) Nantahala Capital Management, LLC ("Nantahala") : 9.39%
(2) Wilmot B. Harkey: 9.39%
(3) Daniel Mack: 9.39%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>(1) Nantahala Capital Management, LLC ("Nantahala") :  0 Shares.
(2) Wilmot B. Harkey:  0 Shares.
(3) Daniel Mack: 0 Shares.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>(1) Nantahala Capital Management, LLC ("Nantahala") :  1,235,000 Shares.
(2) Wilmot B. Harkey:  1,235,000 Shares.
(3) Daniel Mack: 1,235,000 Shares.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>(1) Nantahala Capital Management, LLC ("Nantahala") :  0 Shares.
(2) Wilmot B. Harkey:  0 Shares.
(3) Daniel Mack: 0 Shares.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>(1) Nantahala Capital Management, LLC ("Nantahala") :  1,235,000 Shares.
(2) Wilmot B. Harkey:  1,235,000 Shares.
(3) Daniel Mack: 1,235,000 Shares.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E).  See Item 4(a).</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Nantahala Capital Management, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Taki Vasilakis</signature>
        <title>Taki Vasilakis / Chief Compliance Officer</title>
        <date>11/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Wilmot B. Harkey</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Wilmot B. Harkey</signature>
        <title>Wilmot B. Harkey</title>
        <date>11/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Daniel Mack</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Daniel Mack</signature>
        <title>Daniel Mack</title>
        <date>11/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
